Aug. 17 at 10:23 PM
$OSTX The 10-Q should not be the story with OSTX. The pipeline is.
This is a pre-revenue biotech, so judging it like an established company based on quarterly revenue, EPS or operating losses misses the entire investment thesis.
What matters now is whether the clinical data and regulatory pathway continue to validate OST-HER2. The 10-Q actually shows meaningful progress:
$5M of the potential
$10M financing has already been funded, with additional VAT refunds and R&D tax credits expected to strengthen the runway into 2027. All critical FDA meetings scheduled with the potential to propel this company into another stratosphere.
And the catalysts are weeks away, not months.
Selling a pre-revenue biotech strictly because the income statement looks ugly is like judging a house under construction by how much rent it currently produces.
The next few weeks—not Q2 revenue—are what investors should be watching.
